# SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

> **NCT05057806** · EARLY_PHASE1 · RECRUITING · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 30 (estimated)

## Conditions studied

- Type2 Diabetes
- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** Empagliflozin 25 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05057806
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-13
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05057806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05057806, "SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05057806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*